← Back to Search

Home-Based Rehabilitation for ARSACS (PACE-ARSCS Trial)

N/A
Recruiting
Led By Elise Duchesne, Ph.D
Research Sponsored by Université de Sherbrooke
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
ARSACS diagnosis must be confirmed by genetic analysis
Women and men, aged between 18 and 50 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 12, week 24
Awards & highlights

PACE-ARSCS Trial Summary

This trial will test the effects of a 12-week home-based rehab program on 48 people with ARSACS, measuring changes & acceptability at 3 points.

Who is the study for?
This trial is for men and women aged 18-50 with ARSACS, a genetic disorder affecting movement. Participants must live in the Saguenay-Lac-St-Jean region, be able to stand up from a seated position, and not already be very physically active or in rehab. Pregnant individuals or those with other physical limitations are excluded.Check my eligibility
What is being tested?
The study tests a home-based rehabilitation program over 12 weeks against usual care in people with ARSACS. It involves 48 participants who will be assessed at the start, after the control phase (12 weeks), and post-intervention (24 weeks) to see how effective this individualized program is.See study design
What are the potential side effects?
Since this trial involves rehabilitation exercises tailored for individuals with ARSACS, side effects might include muscle soreness or fatigue due to increased physical activity during the intervention phase.

PACE-ARSCS Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My ARSACS diagnosis was confirmed through genetic testing.
Select...
I am between 18 and 50 years old.
Select...
I can sit down and stand up from a chair on my own.

PACE-ARSCS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 12, week 24
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 12, week 24 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in balance
Change in sitting balance
Change in walking speed
Secondary outcome measures
Change in mobility components
Change in sleep components
Change in social participation
+15 more

PACE-ARSCS Trial Design

1Treatment groups
Experimental Treatment
Group I: Control followed by intervention phaseExperimental Treatment1 Intervention
All participants will participate in 2 phases : control phase (12-week usual care) followed by an intervention phase (12-week home-based rehabilitation program). The rehabilitation program consists of three domains of exercises divided by levels of difficulty: sitting balance (16 levels), standing balance (21 levels) and sit-to-stand transfer (12 levels), including 67 exercises. Each individualized home-based rehabilitation program will include 3 to 6 exercises, for a total duration of 15 to 20 minutes.

Find a Location

Who is running the clinical trial?

Ataxia Charlevoix-Saguenay FoundationUNKNOWN
Université de SherbrookeLead Sponsor
292 Previous Clinical Trials
69,393 Total Patients Enrolled
Elise Duchesne, Ph.DPrincipal InvestigatorUniversité du Québec à Chicoutimi
1 Previous Clinical Trials
12 Total Patients Enrolled

Media Library

Home-based Rehabilitation Program Clinical Trial Eligibility Overview. Trial Name: NCT05768750 — N/A
Spastic Ataxia Research Study Groups: Control followed by intervention phase
Spastic Ataxia Clinical Trial 2023: Home-based Rehabilitation Program Highlights & Side Effects. Trial Name: NCT05768750 — N/A
Home-based Rehabilitation Program 2023 Treatment Timeline for Medical Study. Trial Name: NCT05768750 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this research endeavor encompass individuals over thirty years of age?

"This medical study is inviting individuals aged 18 and younger than 50 to participate."

Answered by AI

Is this experiment currently accessible to participants?

"Affirmative. Clinicaltrials.gov indicates that this medical experiment, first published on December 1st 2022, is actively seeking participants. About 48 individuals must be accepted from a single site to complete the trial."

Answered by AI

How many participants are eligible to join this clinical experiment?

"Affirmative, clinicaltrials.gov verifies that the trial is currently seeking participants which were initially posted on December 1st 2022 and revised March 3rd 2023. A total of 48 patients are needed from a single medical hub."

Answered by AI

Is there an opportunity to volunteer for this research experiment?

"This clinical trial is seeking a total of 48 individuals afflicted with spastic ataxia of Charlevoix-Saguenay and between the ages 18 to 50."

Answered by AI

What is the primary objective of this clinical research?

"The primary endpoint of this trial, assessed at Baseline, week 12 and 24 is alteration in balance. Secondary endpoints include a shift in the Activity-specific Balance Confidence (ABC) Scale score (ranging from 0 - 100, with no confidence indicated by 0 and full confidence represented by 100), change in the quantity of falls reported over the past month, as well as transformation to lower limb coordination measured via Lower Extremity MOtor COordination Test's touched targets during 30 second intervals for each foot."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
A Home-based Rehabilitation in ARSACS
Cynthia Gagnon 2022. "A Home-based Rehabilitation in ARSACS". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05768750.
~14 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top